Format

Send to

Choose Destination
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):129-139. doi: 10.1016/j.pnpbp.2018.01.026. Epub 2018 Feb 17.

Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD.

Author information

1
School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, Israel.
2
Department of Psychology, University of Haifa, Haifa 3498838, Israel.
3
Department of Psychology, University of Haifa, Haifa 3498838, Israel. Electronic address: iakirav@psy.haifa.ac.il.

Abstract

Posttraumatic stress disorder (PTSD) is a debilitating condition highly comorbid with depression. The endocannabinoid (eCB) system and brain-derived neurotrophic factor (BDNF) are suggestively involved in both disorders. We examined whether cannabinoids can prevent the long-term depressive-like symptoms induced by exposure to the shock and situational reminders (SRs) model of PTSD. The CB1/2 receptor agonist WIN55,212-2 (0.5 mg/kg; i.p.), the fatty acid hydrolase (FAAH) inhibitor URB597 (0.3 mg/kg, i.p.) or vehicle were administered 2 h after severe shock. Cannabinoids prevented the shock/SRs-induced alterations in social recognition memory, locomotion, passive coping, anxiety-like behavior, anhedonia, fear retrieval, fear extinction and startle response as well as the decrease in BDNF levels in the hippocampus and prefrontal cortex (PFC). Furthermore, significant correlations were found between depressive-like behaviors and BDNF levels in the brain. The findings suggest that cannabinoids may prevent both depressive- and PTSD-like symptoms following exposure to severe stress and that alterations in BDNF levels in the brains' fear circuit are involved in these effects.

KEYWORDS:

BDNF; Cannabinoids; Depression; Inhibitory avoidance; PTSD

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center